Latest1 information on COVID-19
©2022 Stanford Medicine
Cyberknife Radiosurgery for Locally Advanced Pancreatic Cancer
Not Recruiting
Trial ID: NCT00233415
Purpose
The purpose of the trial is to test the efficacy of combining conventional chemoradiotherapy
with radiosurgery for locally advanced pancreas cancer.
Official Title
Phase II Study to Evaluate the Efficacy of Conventional Chemoradiotherapy Followed by Stereotactic Radiosurgery for Locally Advanced Pancreatic Cancer
Stanford Investigator(s)
Quynh-Thu Le, MD
Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)
Iris C. Gibbs, MD, FACR, FASTRO
Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery
George A. Fisher Jr.
Colleen Haas Chair in the School of Medicine
Eligibility
Inclusion Criteria:- Pancreatic tumors not to exceed 7.5 cm.
- Histologically confirmed malignancies of the pancreas, (ampulla of Vater or
periampullary duodenum, tumors may be included when the head of pancreas is
secondarily involved and unresectable criteria are met).
- Unresectable by CT criteria or unresectable at exploratory laparotomy or laparoscopy.
CT criteria for unresectability include encasement of the superior mesenteric vein
(SMV), portal vein (PV) or invasion of the celiac artery or superior mesenteric artery
(SMA).
- Patients with metastatic disease may be treated if they are symptomatic from the
primary tumor.
- Eastern Clinical Oncology Group performance status 0, 1 or 2. Exclusion
Criteria:Chemotherapy within 1 month of registration.
Intervention(s):
device: Stereotactic Radiosurgery (Cyberknife)
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Stanford Cancer Clinical Trials Office
6504987061